Ionis Pharmaceuticals
IONS
344 hedge funds and large institutions have $5.03B invested in Ionis Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 103 increasing their positions, 123 reducing their positions, and 60 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
32% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $18.8M
3.26% more ownership
Funds ownership: 101.62% → 104.87% (+3.3%)
3% less funds holding
Funds holding: 355 → 344 (-11)
10% less capital invested
Capital invested by funds: $5.61B → $5.03B (-$580M)
12% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 60
16% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 123
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$86.1M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$65.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$62.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$43M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$56.6M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$28.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$26.3M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$20.8M |
| 5 |
State Street
Boston,
Massachusetts
|
-$19M |
IONS Hedge Fund Activity: Q1 2025 in Review
344 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2025, worth a combined $5.03B — down 10% from $5.61B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of IONS and 53 opened new positions — a net loss of 7 holders — while 123 trimmed existing stakes and 103 added.
The largest buyer was Deep Track Capital, adding an estimated $86.1M. The largest seller was ClearBridge Investments, exiting entirely with an estimated $56.6M sold.
- 344 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2025, down from 355 in Q4 2024.
- Funds reported $5.03B of Ionis Pharmaceuticals stock for Q1 2025, down 10% quarter-over-quarter.
- 53 funds opened new Ionis Pharmaceuticals positions in Q1 2025 and 60 closed out, a net change of -7 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2025 was Deep Track Capital, an estimated $86.1M added.
- The largest Ionis Pharmaceuticals seller in Q1 2025 was ClearBridge Investments, an estimated $56.6M sold.
Based on aggregated 13F filings for Q1 2025.